Rocket Pharmaceuticals (RCKT) Operating Leases (2019 - 2026)
Rocket Pharmaceuticals (RCKT) posted Operating Leases of $2.5 million for Q1 2026, down 4.12% sequentially from $2.6 million in Q4 2025, and down 19.45% YoY from $3.1 million in Q1 2025.
Rocket Pharmaceuticals (RCKT) Operating Leases (2019 - 2026) Analysis & Trends
Rocket Pharmaceuticals has reported Operating Leases for 8 years, with the latest figure at $2.5 million in Q1 2026.
- Quarterly Operating Leases fell 19.45% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.5 million (down 19.45% YoY) and the FY2025 annual result came in at $2.6 million, down 20.2% from the prior year.
- Operating Leases retreated to $2.5 million in Q1 2026 per RCKT's latest filing, from $2.6 million in the prior quarter.
- Over five years, Operating Leases peaked at $3.7 million in Q1 2024 and troughed at $200000.0 in Q1 2023.
- A 5-year average of $2.4 million and a median of $2.9 million in 2025 frame the typical range for Operating Leases.
- The sharpest annual moves came in 2023 and 2024: Operating Leases sank 72.18% in 2023, then jumped 1757.0% in 2024.
- Over 5 years, Operating Leases stood at $1.1 million in 2022, then surged by 173.25% to $3.0 million in 2023, then advanced by 9.59% to $3.3 million in 2024, then dropped by 20.2% to $2.6 million in 2025, then retreated by 4.12% to $2.5 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $2.5 million, $2.6 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Rocket Pharmaceuticals | 380.92 Mn | 380.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.49 Mn |
| Mar 31, 2026 | 2.49 Mn |
| Dec 31, 2025 | 2.60 Mn |
| Sep 30, 2025 | 2.76 Mn |
| Jun 30, 2025 | 2.93 Mn |
| Mar 31, 2025 | 3.10 Mn |
| Dec 31, 2024 | 3.26 Mn |
| Sep 30, 2024 | 3.41 Mn |
| Jun 30, 2024 | 3.57 Mn |
| Mar 31, 2024 | 3.71 Mn |
| Dec 31, 2023 | 2.97 Mn |
| Sep 30, 2023 | 2.99 Mn |
| Jun 30, 2023 | 3.07 Mn |
| Mar 31, 2023 | 200,000.00 |
| Dec 31, 2022 | 1.09 Mn |
| Sep 30, 2022 | 492,000.00 |
| Jun 30, 2022 | 606,000.00 |
| Mar 31, 2022 | 719,000.00 |
| Dec 31, 2021 | 905,000.00 |
| Sep 30, 2021 | 891,000.00 |